AGL 38.75 Increased By ▲ 0.05 (0.13%)
AIRLINK 137.10 Decreased By ▼ -0.78 (-0.57%)
BOP 5.37 Decreased By ▼ -0.06 (-1.1%)
CNERGY 3.87 Increased By ▲ 0.09 (2.38%)
DCL 8.09 Increased By ▲ 0.35 (4.52%)
DFML 45.74 Increased By ▲ 0.12 (0.26%)
DGKC 83.30 Increased By ▲ 2.80 (3.48%)
FCCL 30.27 Increased By ▲ 0.72 (2.44%)
FFBL 57.60 Increased By ▲ 1.80 (3.23%)
FFL 9.14 Increased By ▲ 0.05 (0.55%)
HUBC 106.85 Increased By ▲ 1.25 (1.18%)
HUMNL 14.30 Increased By ▲ 0.25 (1.78%)
KEL 4.68 Increased By ▲ 0.38 (8.84%)
KOSM 7.98 Decreased By ▼ -0.25 (-3.04%)
MLCF 38.93 Increased By ▲ 0.95 (2.5%)
NBP 67.60 Decreased By ▼ -1.63 (-2.35%)
OGDC 168.99 Increased By ▲ 1.99 (1.19%)
PAEL 25.38 Increased By ▲ 0.18 (0.71%)
PIBTL 5.94 Decreased By ▼ -0.84 (-12.39%)
PPL 131.00 Increased By ▲ 0.65 (0.5%)
PRL 23.76 No Change ▼ 0.00 (0%)
PTC 15.75 Increased By ▲ 0.05 (0.32%)
SEARL 64.75 Increased By ▲ 3.27 (5.32%)
TELE 7.40 Increased By ▲ 0.36 (5.11%)
TOMCL 36.09 Decreased By ▼ -0.01 (-0.03%)
TPLP 7.86 Increased By ▲ 0.05 (0.64%)
TREET 14.93 Decreased By ▼ -0.22 (-1.45%)
TRG 45.25 Increased By ▲ 0.36 (0.8%)
UNITY 25.83 Increased By ▲ 0.32 (1.25%)
WTL 1.29 Increased By ▲ 0.02 (1.57%)
BR100 9,347 Increased By 123.7 (1.34%)
BR30 28,113 Increased By 346.6 (1.25%)
KSE100 87,195 Increased By 728 (0.84%)
KSE30 27,397 Increased By 234 (0.86%)

ROME: A top official in the European Medicines Agency said it might be worth abandoning AstraZeneca’s coronavirus vaccine for all age groups where alternatives are available, in an interview published Sunday.

Marco Cavaleri, the EMA’s head of vaccine strategy, also told Italy’s La Stampa newspaper that the Johnson & Johnson jab should be preferentially used for the over 60s.

Both so-called viral vector vaccines are authorised for everyone over 18 but have been dogged by reports of rare blood clots. The EU has also authorised two mRNA vaccines, Pfizer/BioNTech and Moderna.

Italy on Saturday restricted AstraZeneca vaccines to people aged 60 and over following concerns about the heightened health risks for younger people.

Asked if it would not be better to ban AstraZeneca including for the over 60s, Cavaleri said: “Yes, and it is an option that many countries, such as France and Germany, are considering in the light of the increased availability of mRNA vaccines.

“However, incidents were very rare and after the first dose. It is true that there is less data on the second dose, but in the United Kingdom it (the vaccination programme) is going well.”

He added: “Among young people the risks of illness decrease, and the message for them could be to use preferentially the mRNA vaccines, but the choice is left to individual states.”

Comments

Comments are closed.